Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis

• Status: Completed
• Trial end date: 2009-03-01
• Target enrollment: 0
• Participant gender: Female

Summary

This study will determine whether treatment with AMG 162 can prevent lumbar spine bone loss in both early and late postmenopausal women with osteopenia, and to further test the safety and tolerability of AMG 162 in this population.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Amgen
• Treatments: Denosumab

Criteria

Eligibility Criteria

• Postmenopausal women with Osteopenia (lumbar spine bone mineral density T-score between 1.0 and -2.5)